Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897593997> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2897593997 endingPage "viii663" @default.
- W2897593997 startingPage "viii662" @default.
- W2897593997 abstract "Background: Capecitabine is an oral prodrug of the anti-cancer drug 5-fluorouracil (5-FU). The 5-FU degrading enzyme, dihydropyrimidine dehydrogenase, and the target enzyme thymidylate synthase, are subject to circadian rhythmicity. The primary aims of this study were to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), recommended dose (RD) and safety of capecitabine therapy adapted to this circadian rhythm (chronomodulated therapy). Methods: Patients aged ≥ 18 years, with WHO performance status of ≤ 2, and advanced solid tumors potentially benefitting from capecitabine therapy were enrolled. DPYD*2A or 2846A>T mutation carriers were excluded. A classical dose escalation 3 + 3 design was applied. Capecitabine was administered twice daily without interruptions. The daily dose was divided in morning and evening doses that were administered at 09:00h and 24:00h, respectively. The ratio of the morning to the evening dose was 3:5 (morning:evening). Toxicity was assessed according to the Common Terminology Criteria for Adverse Events version 4.03. DLT was evaluated during the first three weeks of treatment. Results: A total of 21 patients was enrolled. The daily capecitabine dose was escalated from 1000 mg/m2 up to 2550 mg/m2 over five dose-levels. Three DLTs were observed in two patients at the highest dose-level (grade III hand-foot syndrome (2x) and grade III diarrhea (1x)). The MTD was established at 2000 mg/m2 per day (750 mg/m2 at 9:00 h and 1250 mg/m2 at 24:00 h). Continuous chronomodulated capecitabine therapy was generally well tolerated at the MTD level with main adverse events being grade 1-2 hand-foot syndrome and fatigue. Conclusions: The cumulative dose of capecitabine at the MTD/RD (i.e., 750 mg/m2 at 9:00h and 1250 mg/m2 at 24:00h, continuous chronomodulated regimen) is 20% higher than the cumulative dose of the approved regimen (1250 mg/m2 bi-daily on day 1-14 of every 21-day cycle). Chronomodulation therefore represents a promising strategy as it could lead to improved tolerability and efficacy of capecitabine. Further investigation is warranted. Clinical trial identification: EudraCT: 2014-000889-22. Legal entity responsible for the study: The Netherlands Cancer Institute. Funding: The Netherlands Cancer Institute. Disclosure: All authors have declared no conflicts of interest." @default.
- W2897593997 created "2018-10-26" @default.
- W2897593997 creator A5000418012 @default.
- W2897593997 creator A5004886070 @default.
- W2897593997 creator A5010531755 @default.
- W2897593997 creator A5035604811 @default.
- W2897593997 creator A5041259777 @default.
- W2897593997 creator A5053650233 @default.
- W2897593997 creator A5059722437 @default.
- W2897593997 creator A5062227574 @default.
- W2897593997 creator A5085958205 @default.
- W2897593997 date "2018-10-01" @default.
- W2897593997 modified "2023-10-14" @default.
- W2897593997 title "Phase I pharmacological study of continuous chronomodulated capecitabine treatment" @default.
- W2897593997 doi "https://doi.org/10.1093/annonc/mdy303.042" @default.
- W2897593997 hasPublicationYear "2018" @default.
- W2897593997 type Work @default.
- W2897593997 sameAs 2897593997 @default.
- W2897593997 citedByCount "0" @default.
- W2897593997 crossrefType "journal-article" @default.
- W2897593997 hasAuthorship W2897593997A5000418012 @default.
- W2897593997 hasAuthorship W2897593997A5004886070 @default.
- W2897593997 hasAuthorship W2897593997A5010531755 @default.
- W2897593997 hasAuthorship W2897593997A5035604811 @default.
- W2897593997 hasAuthorship W2897593997A5041259777 @default.
- W2897593997 hasAuthorship W2897593997A5053650233 @default.
- W2897593997 hasAuthorship W2897593997A5059722437 @default.
- W2897593997 hasAuthorship W2897593997A5062227574 @default.
- W2897593997 hasAuthorship W2897593997A5085958205 @default.
- W2897593997 hasBestOaLocation W28975939971 @default.
- W2897593997 hasConcept C121332964 @default.
- W2897593997 hasConcept C121608353 @default.
- W2897593997 hasConcept C123321153 @default.
- W2897593997 hasConcept C126322002 @default.
- W2897593997 hasConcept C1276947 @default.
- W2897593997 hasConcept C143998085 @default.
- W2897593997 hasConcept C19720800 @default.
- W2897593997 hasConcept C197934379 @default.
- W2897593997 hasConcept C2776476923 @default.
- W2897593997 hasConcept C2776694085 @default.
- W2897593997 hasConcept C2777793932 @default.
- W2897593997 hasConcept C2777909004 @default.
- W2897593997 hasConcept C2778050828 @default.
- W2897593997 hasConcept C2780456651 @default.
- W2897593997 hasConcept C29730261 @default.
- W2897593997 hasConcept C526805850 @default.
- W2897593997 hasConcept C71924100 @default.
- W2897593997 hasConcept C90924648 @default.
- W2897593997 hasConcept C98274493 @default.
- W2897593997 hasConceptScore W2897593997C121332964 @default.
- W2897593997 hasConceptScore W2897593997C121608353 @default.
- W2897593997 hasConceptScore W2897593997C123321153 @default.
- W2897593997 hasConceptScore W2897593997C126322002 @default.
- W2897593997 hasConceptScore W2897593997C1276947 @default.
- W2897593997 hasConceptScore W2897593997C143998085 @default.
- W2897593997 hasConceptScore W2897593997C19720800 @default.
- W2897593997 hasConceptScore W2897593997C197934379 @default.
- W2897593997 hasConceptScore W2897593997C2776476923 @default.
- W2897593997 hasConceptScore W2897593997C2776694085 @default.
- W2897593997 hasConceptScore W2897593997C2777793932 @default.
- W2897593997 hasConceptScore W2897593997C2777909004 @default.
- W2897593997 hasConceptScore W2897593997C2778050828 @default.
- W2897593997 hasConceptScore W2897593997C2780456651 @default.
- W2897593997 hasConceptScore W2897593997C29730261 @default.
- W2897593997 hasConceptScore W2897593997C526805850 @default.
- W2897593997 hasConceptScore W2897593997C71924100 @default.
- W2897593997 hasConceptScore W2897593997C90924648 @default.
- W2897593997 hasConceptScore W2897593997C98274493 @default.
- W2897593997 hasLocation W28975939971 @default.
- W2897593997 hasLocation W28975939972 @default.
- W2897593997 hasOpenAccess W2897593997 @default.
- W2897593997 hasPrimaryLocation W28975939971 @default.
- W2897593997 hasRelatedWork W1998631092 @default.
- W2897593997 hasRelatedWork W2047969495 @default.
- W2897593997 hasRelatedWork W2182963545 @default.
- W2897593997 hasRelatedWork W2412069692 @default.
- W2897593997 hasRelatedWork W2759157454 @default.
- W2897593997 hasRelatedWork W2804440574 @default.
- W2897593997 hasRelatedWork W2807835282 @default.
- W2897593997 hasRelatedWork W2891694686 @default.
- W2897593997 hasRelatedWork W3003604645 @default.
- W2897593997 hasRelatedWork W4307910076 @default.
- W2897593997 hasVolume "29" @default.
- W2897593997 isParatext "false" @default.
- W2897593997 isRetracted "false" @default.
- W2897593997 magId "2897593997" @default.
- W2897593997 workType "article" @default.